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Objectives
Objective 1: To describe essential cannabis pharmacokinetics
Objective 2: To describe the potential uses and pitfalls of drug testing in 
OUI cases
Definitions
• Cannabis
• Marijuana
• Cannabinoids
• Delta-9-tetrahydrocannabinol (THC)

Marijuana


Delta-9-tetrahydrocannabinol (THC)
Delta-9-tetrahydrocannabinol 
11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) 
11-nor-9-carboxy-THC (THC-COOH)
• Inactive
• May persist in urine for weeks
Pharmacokinetics
Highly variable between individuals
Differences between smoked, vaporized, and ingested forms
Smoked marijuana: peak concentration in 3-10 minutes
Less predictable after ingestion
Chronic use causes THC deposition in fatty tissues
Testing Methods
Blood/Serum
Oral fluid
Urine
Blood/serum THC
Tetrahydrocannabinol concentrations are only measurable within the 
first 2 h of smoking marijuana, while the psychomotor effects may last 
8 h or more
An undetectable THC concentration does not rule out driver 
impairment due to marijuana consumption
Blood/serum THC
Even short delays can alter results (leading to zero-tolerance laws)
Unlike alcohol, no back extrapolation of concentrations
Serum THC concentration 7–10 ng/ml is equivalent to a blood alcohol 
concentration of 0.05 g/dL
Some authors recommend lowering cutoffs if alcohol also present
International approaches to driving under the influence of 
cannabis: A review of evidence on impact. Drug and Alcohol 
Dependence.
Evaluating THC to THC-COOH ratios (CIF)
In six volunteers, peak serum THC concentrations occurred at 8 
minutes (range, 6–10 minutes) after onset of smoking, peak 11-OH-THC 
at 13 minutes (range, 9–23 minutes), and peak THC-COOH at 120 
minutes (range, 48–240 minutes).
Approximately 1 hour after beginning to smoke a marijuana cigarette, 
the THC to 11-OH-THC ratio is 3:1, and the THC to THC-COOH ratio is 
1:2
At approximately 2 hours, the ratios are 2.5:1 and 1:8, respectively
At 3 hours, the ratios are 2:1 and 1:16, respectively
Oral Fluid Testing
Cannabidiol concentrations do not correlate with level of impairment
Cannabinoid glucuronide measurements
THC and CBD in blood samples and seizures in Norway: Does 
CBD affect THC-induced impairment in apprehended subjects? 
Forensic Sci International. 2017.
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